Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, today announced that the Australian Patent Office has granted a key patent covering the use of the company’s allogeneic "off-the-shelf" stem cell technology for the treatment of osteoarthritis and other inflammatory conditions for human and animal applications.
Australian patent number 2012313352, entitled “Stem cells and secretions for treatment of inflammatory conditions” provides commercial rights in Australia through to 20 September 2032. This patent is also being pursued for grant in other key territories including the USA, Japan and Europe.
The patent underpins the company’s Progenza stem cell technology which is a combination of mesenchymal stem cells and secretions from the cells. The secretions are the molecules (including cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions from adipose (fat)-derived MSCs and has shown that a combination of cells and secretions has a more powerful therapeutic effect than cells alone.
This patent is complimented by another Regeneus Australian patent granted in December 2014 that uses the company’s secretions technology to maintain viability and functionality of MSCs during the freezing and thawing process.
Regeneus’ Progenza technology is the subject of a Phase 1 study for the treatment of knee osteoarthritis in humans, which commenced in Q1 FY16 and is scheduled for final safety readout in Q4 FY16.
Regeneus has 49 patents or patent applications across 14 patent families, which provides a substantial Intellectual Property position for the company’s product pipeline.